Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16717704 | 0.70 | GAA (0.42) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL23127930 | 0.68 | — | — | |
| SCHEMBL19400 | 0.68 | — | — | |
| SCHEMBL582683 | 0.68 | — | — | |
| SCHEMBL7172665 | 0.65 | GAA (0.39) | GAANOX1MAPTMEN1KMT2A | |
| SCHEMBL57942 | 0.65 | — | — | |
| SCHEMBL11286921 | 0.64 | ALDH1A1 (0.44) | GAANOX1MAPTMEN1KMT2A | |
| SCHEMBL3469293 | 0.64 | ALDH1A1 (0.44) | GAANOX1MAPTMEN1KMT2A | |
| SCHEMBL207246 | 0.64 | GAA (0.38) | GAANOX1MAPTMEN1KMT2A | |
| SCHEMBL226035 | 0.62 | GAA (0.41) | GAANOX1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | claimed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| US-5955481-A | Pyridine type thiazolidines | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | claimed |
| EP-2638544-B1 | PHOTOPOLYMER FORMULATION FOR PRODUCING HOLOGRAPHIC MEDIA HAVING HIGHLY CROSS-LINKED MATRIX POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2018-12-26 | — | — | EP | disclosed |
| US-9760060-B2 | Photopolymer formulations for producing holographic media having highly crosslinked matrix polymers | COVESTRO DEUTSCHLAND AG (DE) | 2017-09-12 | — | — | US | disclosed |
| US-20160054704-A1 | PHOTOPOLYMER FORMULATIONS FOR PRODUCING HOLOGRAPHIC MEDIA HAVING HIGHLY CROSSLINKED MATRIX POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2016-02-25 | — | — | US | disclosed |
| US-9146456-B2 | Photopolymer formulation for producing holographic media having highly crosslinked matrix polymers | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130224634-A1 | PHOTOPOLYMER FORMULATION FOR PRODUCING HOLOGRAPHIC MEDIA HAVING HIGHLY CROSSLINKED MATRIX POLYMERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| EP-0717736-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1996-06-26 | — | — | EP | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| WO-1996011196-A1 | PYRAZOLYLMETHYL-THIAZOLIDINES USEFUL AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | disclosed |
| WO-1995007269-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1995-03-16 | — | — | WO | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | GAA 2807/4885NOX1 1823/4885MAPT 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.